Showing results (51-60 of 96) with videos related to
Sort By:
Pageof 10
Lancet (London, England)|November 10, 2022
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialShweta Urva, Tamer Coskun, Mei Teng Loh, et al.Nature Communications|December 31, 2024
Brainstem BDNF neurons are downstream of GFRAL/GLP1R signallingClaire H Feetham, Valeria Collabolletta, Amy A Worth, et al.Regulatory Peptides|April 11, 2003
Synthesis of biologically active canine CCK-58Joseph R Reeve, David A Keire, Tamer Coskun, et al.Diabetes|August 25, 2016
FGF21 Improves the Adipocyte Dysfunction Related to Seipin DeficiencyLucile Dollet, Clara Levrel, Tamer Coskun, et al.The Journal of Clinical Endocrinology and Metabolism|May 25, 2024
Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal TestKieren J Mather, Andrea Mari, Tim Heise, et al.Journal of Lipid Research|March 26, 2021
Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP miceRobin van Eenige, Zhixiong Ying, Lauren Tambyrajah, et al.Endocrinology|November 13, 2012
Activation of prostaglandin E receptor 4 triggers secretion of gut hormone peptides GLP-1, GLP-2, and PYYTamer Coskun, Libbey S O'Farrell, Samreen K Syed, et al.Diabetes Care|March 1, 2023
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 DiabetesTim Heise, J Hans DeVries, Shweta Urva, et al.Diabetes, Obesity & Metabolism|July 29, 2025
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipidsYi Wen, Deven Lemen, Yanzhu Lin, et al.Plos One|August 28, 2015
Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in MiceDaniel A Briere, Xiaoping Ruan, Christine C Cheng, et al.Pageof 10